中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

9 records (took 0.016 seconds)

    BICYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
    1.
    发明申请
    BICYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER 有权

    公开(公告)号：US20210387985A1

    公开(公告)日：2021-12-16

    申请号：US17354010

    申请日：2021-06-22

    Applicant: Tempest Therapeutics, Inc.

    Inventor： Yalda BRAVO ,  Jason David BURCH ,  Austin Chih-Yu CHEN ,  Joe Fred NAGAMIZO

    IPC: C07D471/04 ,  C07D209/18 ,  C07D231/56 ,  A61P35/00 ,  C07D235/08

    Abstract: The present disclosure is directed to novel compounds of Formula I and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g. controlling, alleviating, or slowing the progression of) of cancer, including glioblastoma, bone cancer, head and neck cancer, melanoma, basal cell carcinoma, squamous cell carcinoma, adenocarcinoma, oral cancer, esophageal cancer, gastric cancer, intestinal cancer, colon cancer, bladder cancer, hepatocellular carcinoma, renal cell carcinoma, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, and prostate cancer. The compounds of the disclosure are selective antagonists of the EP4 receptor and useful treatment of various diseases that may be ameliorated with blockade of PGE2-mediated signaling.

    PYRAZOLONE COMPOUNDS AND USES THEREOF
    6.
    发明申请
    PYRAZOLONE COMPOUNDS AND USES THEREOF 审中-公开

    公开(公告)号：US20180079745A1

    公开(公告)日：2018-03-22

    申请号：US15829514

    申请日：2017-12-01

    Applicant: Tempest Therapeutics, Inc.

    Inventor： Nicholas Simon STOCK ,  Austin Chih-Yu CHEN ,  Yalda Mostofi BRAVO ,  Jason Duarte JACINTHO ,  Yen TRUONG

    IPC: C07D405/10 ,  C07D401/12 ,  C07D231/20 ,  C07D231/54 ,  C07D401/10

    CPC classification number: C07D405/10 ,  C07D231/20 ,  C07D231/54 ,  C07D401/10 ,  C07D401/12

    Abstract: The invention disclosed herein is directed to compounds of Formula I [Formula should be entered here] and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, acute or chronic myeloid leukemia, melanoma, and other cancers. The invention also includes pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, acute or chronic myeloid leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, acute or chronic myeloid leukemia, melanoma and other cancers through the administration of a therapeutically effective amount of a selective PPARa antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections.

    BICYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
    9.
    发明申请
    BICYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER 审中-公开

    公开(公告)号：US20200283438A1

    公开(公告)日：2020-09-10

    申请号：US16880756

    申请日：2020-05-21

    Applicant: Tempest Therapeutics, Inc.

    Inventor： Yalda BRAVO ,  Jason David BURCH ,  Austin Chih-Yu CHEN ,  Joe Fred NAGAMIZO

    IPC: C07D471/04 ,  C07D209/18 ,  C07D231/56 ,  C07D235/08 ,  A61P35/00

    Abstract: The present disclosure is directed to novel compounds of Formula I and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of cancer, including glioblastoma, bone cancer, head and neck cancer, melanoma, basal cell carcinoma, squamous cell carcinoma, adenocarcinoma, oral cancer, esophageal cancer, gastric cancer, intestinal cancer, colon cancer, bladder cancer, hepatocellular carcinoma, renal cell carcinoma, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, and prostate cancer. The compounds of the disclosure are selective antagonists of the EP4 receptor and useful treatment of various diseases that may be ameliorated with blockade of PGE2-mediated signaling.

Patent Agency Ranking